Entera Bio Statistics
Total Valuation
Entera Bio has a market cap or net worth of $62.52 million. The enterprise value is $58.83 million.
Important Dates
The last earnings date was Friday, May 8, 2026, after market close.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Entera Bio has 49.23 million shares outstanding. The number of shares has increased by 20.29% in one year.
| Current Share Class | 49.23M |
| Shares Outstanding | 49.23M |
| Shares Change (YoY) | +20.29% |
| Shares Change (QoQ) | +1.02% |
| Owned by Insiders (%) | 2.17% |
| Owned by Institutions (%) | 4.09% |
| Float | 36.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.54 |
| P/TBV Ratio | 5.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.93, with a Debt / Equity ratio of 0.04.
| Current Ratio | 7.93 |
| Quick Ratio | 2.63 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -82.33% and return on invested capital (ROIC) is -50.86%.
| Return on Equity (ROE) | -82.33% |
| Return on Assets (ROA) | -45.01% |
| Return on Invested Capital (ROIC) | -50.86% |
| Return on Capital Employed (ROCE) | -108.24% |
| Weighted Average Cost of Capital (WACC) | 12.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$562,591 |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.44% in the last 52 weeks. The beta is 1.55, so Entera Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | -37.44% |
| 50-Day Moving Average | 1.21 |
| 200-Day Moving Average | 1.77 |
| Relative Strength Index (RSI) | 52.91 |
| Average Volume (20 Days) | 115,302 |
Short Selling Information
The latest short interest is 192,284, so 0.39% of the outstanding shares have been sold short.
| Short Interest | 192,284 |
| Short Previous Month | 192,781 |
| Short % of Shares Out | 0.39% |
| Short % of Float | 0.52% |
| Short Ratio (days to cover) | 0.87 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.51M |
| Pretax Income | -12.38M |
| Net Income | -12.38M |
| EBITDA | -12.48M |
| EBIT | -12.51M |
| Earnings Per Share (EPS) | -$0.26 |
Full Income StatementBalance Sheet
The company has $4.14 million in cash and $448,000 in debt, with a net cash position of $3.69 million or $0.07 per share.
| Cash & Cash Equivalents | 4.14M |
| Total Debt | 448,000 |
| Net Cash | 3.69M |
| Net Cash Per Share | $0.07 |
| Equity (Book Value) | 10.69M |
| Book Value Per Share | 0.23 |
| Working Capital | 10.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.06 million and capital expenditures -$99,000, giving a free cash flow of -$9.16 million.
| Operating Cash Flow | -9.06M |
| Capital Expenditures | -99,000 |
| Depreciation & Amortization | 29,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -9.16M |
| FCF Per Share | -$0.19 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Entera Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.29% |
| Shareholder Yield | -20.29% |
| Earnings Yield | -19.80% |
| FCF Yield | -14.64% |
Analyst Forecast
The average price target for Entera Bio is $9.00, which is 608.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 608.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Entera Bio has an Altman Z-Score of 5.59 and a Piotroski F-Score of 1.
| Altman Z-Score | 5.59 |
| Piotroski F-Score | 1 |
